证券简称：国新健康 证券代码：000503 编号：2025-41 国新健康保障服务集团股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次股东大会的议案 10 需经出席会议的股东所持表决权的三分之二以上通 过，公司限制性股票激励计划（第一期）的激励对象作为关联股东，对该议案回 避表决。 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第十一届董事会第三十八次会议暨 2024 年度会议，审议通过了《关于 召开公司 2024 年度股东大会的议案》，现将股东大会有关事项公告如下： 一、召开会议的基本情况 （一）股东大会届次：2024 年度股东大会 （二）会议召集人：公司董事会 （三）会议召开的合法、合规性：本次股东大会召开符合有关法律、行政法 规、部门规章、规范性文件、深圳证券交易所业务规则和《公司章程》等的规定。 （四）召开时间： 1．现场会议召开时间为：2025 年 6 月 26 日 15:00 2．网络投票时间为：2025 年 6 月 26 日。其中，通 ...

证券简称：国新健康 证券代码：000503 编号：2025-37 国新健康保障服务集团股份有限公司 第十二届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 表决结果：3票赞成，0票反对，0票弃权。 本议案尚需提交公司股东大会审议。 具体内容详见同日在《中国证券报》《上海证券报》《证券时报》及巨潮 资讯网（网址：www.cninfo.com.cn）披露的《关于限制性股票激励计划(第一期) 回购注销剩余全部限制性股票的公告》（公告编号：2025-39）。 二、关于增加使用暂时闲置募集资金进行现金管理的额度的议案 公司（含国新健康保障服务有限公司、北京海协智康科技发展有限公司、 1 国新健康保障服务集团股份有限公司（以下简称"公司"）第十二届监事 会第二次会议于2025年5月28日发出会议通知，会议由监事会主席程志鹏先生召 集并主持，于2025年6月5日以通讯方式召开。本次会议应出席监事3人，实际出 席监事3人。会议的召开符合有关法律、行政法规、部门规章和《公司章程》规 定。 本次会议以记名投票方式表决，审议通过了如下议案： 一、关于限制性 ...

监事会认为上述回购注销限制性股票事项符合法律、法规、规范性文件及公 司《激励计划》等相关规定，程序合法合规，同意公司按规定回购注销上述限制 性股票。 国新健康保障服务集团股份有限公司 监 事 会 二零二五年六月五日 国新健康保障服务集团股份有限公司监事会 关于限制性股票激励计划（第一期）回购注销剩余全部限制性 股票的核查意见 国新健康保障服务集团股份有限公司（以下简称"公司"）监事会依据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司股权激励管理办法》 《关于规范国有控股上市公司实施股权激励制度有关问题的通知》《中央企业控 股上市公司实施股权激励工作指引》等有关法律、法规及规范性文件和《国新健 康保障服务集团股份有限公司章程》的规定，对公司回购注销限制性股票激励计 划（第一期）的剩余全部限制性股票事项进行核查，发表核查意见如下： 根据《国新健康保障服务集团股份有限公司限制性股票激励计划（第一期） （草案修订稿）》（以下简称《激励计划》）的规定，鉴于2024年公司业绩考核 未达标，公司本次激励计划首次授予第三个解除限售期解除限售条件未成就，须 对首次授予激励对象第三个解除限售期对应的限制性股票按照授 ...

证券简称：国新健康 证券代码：000503 编号：2025-36 国新健康保障服务集团股份有限公司 第十二届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十二届董事 会第二次会议于2025年5月28日发出会议通知，会议由董事长李永华先生召集并 主持，于2025年6月5日以现场结合通讯方式召开。本次会议应出席董事9人，实 际出席董事9人，公司监事和高级管理人员列席会议。会议的召开符合有关法律、 行政法规、部门规章和《公司章程》规定。 本次会议以记名投票方式表决，审议通过了如下议案： 一、关于续聘2025年度会计师事务所及确定其报酬的议案 同意公司续聘中证天通会计师事务所（特殊普通合伙）为公司2025年度审 计机构，拟确定2025年度审计服务报酬总额为人民币105万元，其中年度报告审 计服务报酬76万元，内部控制审计服务报酬29万元，拟确定的2025年度审计服 务报酬总额和构成与2024年度保持不变。 表决情况：9票赞成，0票反对，0票弃权。 本议案已经公司审计委员会审议通过，尚需提 ...

Group 1 - The core viewpoint of the news is that Guo Xin Health has shown a slight increase in stock price and has a significant market capitalization, but its financial performance indicates challenges with negative net profit and low gross margin [1] - As of the first quarter of 2025, seven institutions hold shares in Guo Xin Health, with a total shareholding of 26,554.10 million shares valued at 2.881 billion yuan [1] - The main business of Guo Xin Health includes digital medical insurance, digital medicine, digital healthcare, and health services, with the latest revenue reported at 50.47 million yuan, reflecting a year-on-year increase of 5.33% [1] Group 2 - Guo Xin Health's price-to-earnings (PE) ratio is significantly negative at -661.13, indicating potential overvaluation compared to the industry average PE of 111.54 [2] - The company's market-to-book ratio stands at 7.57, which is higher than the industry median of 3.75, suggesting a premium valuation [2] - The total market capitalization of Guo Xin Health is reported at 10.294 billion yuan, positioning it within the context of other companies in the industry [2]

Core Points - The company successfully held its first extraordinary general meeting of shareholders in 2025, where the election of the twelfth board of directors and supervisory board took place [2][3] - Li Yonghua was elected as the chairman of the twelfth board of directors, and the meeting complied with all relevant laws and regulations [3] - A total of 293 shareholders participated in the voting, representing 285,603,057 shares, which accounted for 29.1042% of the total voting shares [2] Board and Supervisory Board Elections - The twelfth board of directors consists of 9 members, including 6 non-independent directors and 3 independent directors [2] - The supervisory board is composed of 3 members, with Cheng Zhipeng elected as the chairman [4] Management Appointments - The board appointed Yuan Hongquan as the general manager and several individuals to key management positions, including Liu Yingjie and Zhang Zhenhua as deputy general managers [6] - The appointments are effective from the date of approval by the board until the end of the twelfth board's term [6] Strategic Focus - The company aims to drive high-quality development through its strategic planning centered on "three medical collaborations, innovation-driven, and digital ecology" [9]

Group 1 - The company announced that the funds in its fundraising account, which were previously frozen, have been fully released [1][2] - The frozen amount was RMB 577,636.80, which was frozen by the Nanchang High-tech Industrial Development Zone People's Court on April 24, 2025 [1] - The company will continue to monitor the status of the fundraising account to protect the legal rights of the company and all shareholders [2] Group 2 - The notification regarding the release of the frozen funds was received from the Beijing Branch of China Merchants Bank [2] - The fundraising account has been restored to normal status following the release of the funds [2] - The company has disclosed the relevant information in various financial news outlets and platforms [1]

证券简称：国新健康 证券代码：000503 编号：2025-35 一、募集资金专户被冻结的基本情况 公司全资子公司国新有限的募集资金专用账户（账号：110908747610001） 于 2025 年 4 月 24 日被南昌高新技术产业开发区人民法院实施司法冻结，冻结金 额为人民币 577,636.80 元，法律文书：(2025)赣 0191 执保 477 号之一。 具体内容详见公司于 2025 年 4 月 29 日在《中国证券报》《上海证券报》 《证券时报》及巨潮资讯网（网址：www.cninfo.com.cn）披露的《关于公司募集 资金账户部分资金被冻结的公告》（公告编号：2025-28）。 二、募集资金解除冻结的进展情况 近日，公司收到招商银行北京分行北三环支行通知，公司被冻结的募集资金 专用账户资金金额 577,636.80 元人民币已解除冻结，并且募集资金账户已恢复至 正常状态。公司将持续关注募集资金账户情况，依法维护公司与全体股东的合法 权益。 三、备查文件 《招商银行关于国新有限募集资金账户资金解除冻结的通知》 特此公告。 国新健康保障服务集团股份有限公司 关于公司募集资金账户部分资金解除冻结的公 ...

Group 1 - The DRG/DIP concept declined by 3.30%, ranking among the top declines in the concept sector, with notable declines in companies such as Chuangying Huikang, ST Yilianzhong, and Jiahe Meikang [1][2] - The DRG/DIP concept experienced a net outflow of 4.92 billion yuan in main funds, with 19 stocks seeing net outflows, and 13 stocks with outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Donghua Software, with a net outflow of 1.26 billion yuan, followed by Chuangying Huikang, Weining Health, and Dian Diagnosis [2][3] Group 2 - The top stocks with net outflows in the DRG/DIP concept included Donghua Software (-3.97%), Chuangying Huikang (-6.76%), and Weining Health (-4.60%) [2][3] - Conversely, the stocks with net inflows included Huaping Co., Guoke Hengtai, and Wanda Information, with net inflows of 238.84 million yuan, 166.15 million yuan, and 121.00 million yuan respectively [2]

Group 1 - The core business of Guo Xin Health includes digital medical insurance, digital medicine, digital healthcare, and health services [1] - As of the first quarter of 2025, Guo Xin Health reported a revenue of 50.47 million yuan, representing a year-on-year increase of 5.33% [1] - The net profit for the same period was -45.58 million yuan, showing a year-on-year decline of 12.86%, with a sales gross margin of -14.79% [1] Group 2 - Guo Xin Health's latest closing price was 10.36 yuan, down 2.63%, with a price-to-book ratio of 7.48 and a total market capitalization of 10.166 billion yuan [1] - A total of 7 institutions held shares in Guo Xin Health, with a combined holding of 265.54 million shares valued at 2.881 billion yuan [1] - The company has a significantly high PE ratio of -652.94, compared to the industry average of 113.16 [2]